MX2018003887A - Derivados de 2-aminoquinazolina como inhibidores de cinasa p70s6. - Google Patents
Derivados de 2-aminoquinazolina como inhibidores de cinasa p70s6.Info
- Publication number
- MX2018003887A MX2018003887A MX2018003887A MX2018003887A MX2018003887A MX 2018003887 A MX2018003887 A MX 2018003887A MX 2018003887 A MX2018003887 A MX 2018003887A MX 2018003887 A MX2018003887 A MX 2018003887A MX 2018003887 A MX2018003887 A MX 2018003887A
- Authority
- MX
- Mexico
- Prior art keywords
- optionally substituted
- hydrogen
- alkylene group
- group
- membered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a un compuesto que inhibe o modula la actividad de cinasa p70S6, los compuestos son de la fórmula (1): (ver fórmula 1) o una sal, tautómero o N-óxido del mismo; en donde: uno de Y y Z es R3 y el otro es Ar2; Q1 es grupo alquileno C1-8 opcionalmente sustituido; y en donde un átomo de carbono del grupo alquileno C1-8 puede opcionalmente ser reemplazado por un grupo ciclopropan-1,1-diilo o ciclobutan-1,1-diilo siempre que el número total de átomos de carbono en un grupo alquileno que contiene tal reemplazo que no excede 8; Q2 es un enlace o un grupo alquileno C1-8 opcionalmente sustituido; R1 se selecciona de hidrógeno, NRxRy y un grupo Cy1; Rx y Ry son cada uno seleccionados de hidrógeno, hidrocarbilo C1-4 o hidroxi-hidrocarbilo C1-4; o NRxRy forma un anillo heterocíclico de 4 a 7 elementos opcionalmente sustituido; Cy1 es un carbocíclico o heterocíclico no aromático monocíclico de 3 a 7 elementos opcionalmente sustituido unido a C; R2 y R4 son cada uno seleccionados de hidrógeno, flúor, cloro, alquilo C1-2 opcionalmente sustituido y alcoxi C1-2 opcionalmente sustituido; R3 se selecciona de hidrógeno, flúor, cloro, alquilo C1-2 opcionalmente sustituido y alcoxi C1-2 opcionalmente sustituido; Ar1 es un anillo arilo o heteroarilo de 5 o 6 elementos monocíclico opcionalmente sustituido; y Ar2 es un grupo heteroarilo de 8 a 11 elementos bicíclico opcionalmente sustituido. Los compuestos son útiles en medicina, por ejemplo, en el tratamiento de una condición o enfermedad seleccionada de cánceres, enfermedades del neurodesarrollo y enfermedades neurodegenerativas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1517451.9A GB201517451D0 (en) | 2015-10-02 | 2015-10-02 | Pharmaceutical compounds |
| GBGB1614037.8A GB201614037D0 (en) | 2016-08-16 | 2016-08-16 | Pharmaceutical compounds |
| PCT/EP2016/073489 WO2017055592A1 (en) | 2015-10-02 | 2016-09-30 | 2-aminoquinazoline derivatives as p70s6 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018003887A true MX2018003887A (es) | 2019-04-01 |
Family
ID=57113310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003887A MX2018003887A (es) | 2015-10-02 | 2016-09-30 | Derivados de 2-aminoquinazolina como inhibidores de cinasa p70s6. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10344033B2 (es) |
| EP (2) | EP3356348B1 (es) |
| JP (1) | JP6821670B2 (es) |
| KR (1) | KR20180061318A (es) |
| CN (1) | CN108473472B (es) |
| AU (1) | AU2016329513B2 (es) |
| CA (1) | CA3000565C (es) |
| CL (1) | CL2018000839A1 (es) |
| ES (1) | ES2967344T3 (es) |
| IL (1) | IL258438B (es) |
| MX (1) | MX2018003887A (es) |
| NZ (1) | NZ740941A (es) |
| PL (1) | PL3868751T3 (es) |
| RU (1) | RU2736123C1 (es) |
| SA (1) | SA518391258B1 (es) |
| WO (1) | WO2017055592A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3356348B1 (en) | 2015-10-02 | 2021-05-05 | Sentinel Oncology Limited | 2-aminoquinazoline derivatives as p70s6 kinase inhibitors |
| US20220112205A1 (en) * | 2020-10-14 | 2022-04-14 | Tosk, Inc. | Heteroaryl Modulators of RAS GTPase |
| WO2023055679A1 (en) * | 2021-10-01 | 2023-04-06 | Merck Sharp & Dohme Llc | C-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| EP4198027A1 (en) * | 2021-12-14 | 2023-06-21 | Universita' Degli Studi di Bari | Sustainable process for the synthesis of molecules with antihistamine activity in unconventional biodegradable solvents (deep eutectic solvents) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| AU2007336893A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for PDK1 inhibition |
| WO2008139152A1 (en) | 2007-05-11 | 2008-11-20 | Sentinel Oncology Limited | N-oxide-containing pharmaceutical compounds |
| WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
| US20100121052A1 (en) | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
| WO2010056320A2 (en) | 2008-11-11 | 2010-05-20 | Tyrogenex, Inc. | Pi3k/mtor kinase inhibitors |
| WO2010056758A1 (en) * | 2008-11-12 | 2010-05-20 | Yangbo Feng | Quinazoline derivatives as kinase inhibitors |
| GB0908905D0 (en) * | 2009-05-26 | 2009-07-01 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| KR101862912B1 (ko) * | 2012-07-20 | 2018-05-30 | 클리브 바이오사이언스 인코포레이티드 (클리브) | p97 복합체의 저해제로서의 축합된 피리미딘 |
| JP6290917B2 (ja) | 2012-11-29 | 2018-03-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | アザキナゾリンカルボキサミド誘導体 |
| CN106488910B (zh) | 2013-10-10 | 2020-07-31 | 亚瑞克西斯制药公司 | Kras g12c的抑制剂 |
| GB201502567D0 (en) | 2015-02-16 | 2015-04-01 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP3356348B1 (en) | 2015-10-02 | 2021-05-05 | Sentinel Oncology Limited | 2-aminoquinazoline derivatives as p70s6 kinase inhibitors |
-
2016
- 2016-09-30 EP EP16778295.2A patent/EP3356348B1/en active Active
- 2016-09-30 RU RU2018110884A patent/RU2736123C1/ru active
- 2016-09-30 MX MX2018003887A patent/MX2018003887A/es unknown
- 2016-09-30 US US15/764,960 patent/US10344033B2/en active Active
- 2016-09-30 CA CA3000565A patent/CA3000565C/en active Active
- 2016-09-30 ES ES21164670T patent/ES2967344T3/es active Active
- 2016-09-30 JP JP2018516710A patent/JP6821670B2/ja active Active
- 2016-09-30 PL PL21164670.8T patent/PL3868751T3/pl unknown
- 2016-09-30 CN CN201680070399.8A patent/CN108473472B/zh active Active
- 2016-09-30 NZ NZ740941A patent/NZ740941A/en unknown
- 2016-09-30 AU AU2016329513A patent/AU2016329513B2/en active Active
- 2016-09-30 KR KR1020187012246A patent/KR20180061318A/ko active IP Right Grant
- 2016-09-30 EP EP21164670.8A patent/EP3868751B1/en active Active
- 2016-09-30 WO PCT/EP2016/073489 patent/WO2017055592A1/en active Application Filing
-
2018
- 2018-03-28 IL IL258438A patent/IL258438B/en active IP Right Grant
- 2018-03-29 CL CL2018000839A patent/CL2018000839A1/es unknown
- 2018-04-01 SA SA518391258A patent/SA518391258B1/ar unknown
-
2019
- 2019-06-14 US US16/442,071 patent/US10730882B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10344033B2 (en) | 2019-07-09 |
| JP6821670B2 (ja) | 2021-01-27 |
| IL258438B (en) | 2020-06-30 |
| CA3000565C (en) | 2023-09-26 |
| AU2016329513B2 (en) | 2020-09-03 |
| US20190292195A1 (en) | 2019-09-26 |
| US20180370975A1 (en) | 2018-12-27 |
| CA3000565A1 (en) | 2017-04-06 |
| CL2018000839A1 (es) | 2018-09-07 |
| WO2017055592A1 (en) | 2017-04-06 |
| EP3356348A1 (en) | 2018-08-08 |
| RU2736123C1 (ru) | 2020-11-11 |
| PL3868751T3 (pl) | 2024-04-08 |
| IL258438A (en) | 2018-05-31 |
| EP3868751C0 (en) | 2023-10-25 |
| CN108473472B (zh) | 2021-02-12 |
| AU2016329513A1 (en) | 2018-04-19 |
| ES2967344T3 (es) | 2024-04-29 |
| BR112018006498A2 (pt) | 2018-10-09 |
| JP2018529728A (ja) | 2018-10-11 |
| US10730882B2 (en) | 2020-08-04 |
| EP3868751A1 (en) | 2021-08-25 |
| KR20180061318A (ko) | 2018-06-07 |
| EP3356348B1 (en) | 2021-05-05 |
| NZ740941A (en) | 2024-03-22 |
| CN108473472A (zh) | 2018-08-31 |
| SA518391258B1 (ar) | 2021-06-27 |
| EP3868751B1 (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| PH12015502047A1 (en) | Novel pyrimidine and pyridine compounds and their usage | |
| NZ732657A (en) | Picolinamides with fungicidal activity and other related compounds | |
| MX2016016516A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| MX2018003887A (es) | Derivados de 2-aminoquinazolina como inhibidores de cinasa p70s6. | |
| NZ726638A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| AR096620A1 (es) | Derivado de aminotriazina y composición farmacéutica que lo comprende | |
| MX2016016538A (es) | Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa. | |
| PH12019502781A1 (en) | Imidazole-containing inhibitors of alk2 kinase | |
| PH12016500885A1 (en) | Novel heterocyclic compounds | |
| MD20160053A2 (ro) | Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative | |
| MX2016008910A (es) | Compuestos de fenil-triazolo-piridina. | |
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
| MX2019006843A (es) | Inhibidor de cdk4/6. | |
| MX2018002738A (es) | Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. | |
| EA201591645A1 (ru) | Hантагонисты, имеющие феноксипиперидиновое ядро в структуре | |
| PH12017502254B1 (en) | Pyrazole derivative or pharmaceutically acceptable salt thereof | |
| MX362059B (es) | Derivados de carbamato/urea. | |
| MX2017012387A (es) | Derivados fusionados triciclicos de 1-(ciclo)alquil piridin-2-ona utiles para el tratamiento de cancer. | |
| EA201600323A1 (ru) | Производные пиперазина и их применение в качестве лекарственного средства | |
| NZ727715A (en) | Novel heterocyclic compounds having prs enzyme inhibitory effect | |
| MX2018014165A (es) | Compuestos heterociclicos utiles como agentes antibacterianos y metodo de produccion. | |
| PH12016501645A1 (en) | Aminopyrazolone derivative |